Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 26;12(7):111.
doi: 10.1038/s41408-022-00701-w.

Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant

Federica Sora  1   2 , Sabrina Giammarco  1 , Anna Maria Raiola  3 , Carmen Di Grazia  3 , Stefania Bregante  3 , Francesca Gualandi  3 , Riccardo Varaldo  3 , Patrizia Chiusolo  1   2 , Simona Sica  1   2 , Luca Laurenti  1   2 , Idanna Innocenti  2 , Francesco Autore  2 , Elisabetta Metafuni  2 , Eugenio Galli  2 , Andrea Bacigalupo  4   5 , Emanuele Angelucci  3
Affiliations

Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant

Federica Sora et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Disease free survival of 157 patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant.
A low transplant score (TS) is identified as red blood cell transfusions (RBC Tx) <20 units and spleen size less than 22 cm. A high TS is identified as red blood cell transfusions (RBC Tx) >20 units and/or spleen size than >22 cm.
See this image and copyright information in PMC

References

    1. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;13:2895–901. doi: 10.1182/blood-2008-07-170449. - DOI - PubMed
    1. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWGMRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) Blood. 2010;9:1703–8. doi: 10.1182/blood-2009-09-245837. - DOI - PubMed
    1. Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31:2726–31. doi: 10.1038/leu.2017.169. - DOI - PubMed
    1. Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70 + version 2.0: mutation and karyotype‐enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36:1769–70. doi: 10.1200/JCO.2018.78.9867. - DOI - PubMed
    1. Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;7:1631–42. doi: 10.1038/s41375-018-0107-z. - DOI - PMC - PubMed

Publication types

MeSH terms